Odyssey Therapeutics, Inc.·4

May 11, 8:30 PM ET

Opipari Anthony W. 4

Research Summary

AI-generated summary

Updated

Odyssey (ODTX) Interim CMO Anthony Opipari Receives ~278K Share Awards

What Happened Anthony W. Opipari, Interim Chief Medical Officer and EVP, Translational Medicine at Odyssey Therapeutics (ODTX), received awards of derivative securities totaling 277,980 shares (250,203 + 27,777) on May 7, 2026 (grants at $0.00). On May 11, 2026 he converted/exercised multiple derivative instruments into common stock (several conversion/exercise entries totaling additional converted shares) and had 4 shares withheld/sold to cover exercise/tax obligations at $18.00 per share for $72. Most conversions/exercises are reported as derivative conversions (no cash paid in filing).

Key Details

  • Grant date: 2026-05-07 — Awards of 250,203 and 27,777 derivative shares, $0.00 exercise price (total 277,980 shares).
  • Conversion/exercise date(s): 2026-05-11 — multiple conversions/exercises reported (examples in filing: 6,965; 541; 18,531; 11,083; 20,000; 17,545; 5,263 shares listed across entries).
  • Tax/withholding: 4 shares disposed at $18.00 each to satisfy exercise/tax withholding, net proceeds $72 (footnote F6).
  • Footnotes: automatic conversions of Series A–D preferred and certain warrants into common stock before the IPO (F1–F5); reverse 1-for-9.7170 split noted (F7); some awards/options carry time-based monthly vesting starting June 7, 2026 (F8) and a market-cap milestone vesting condition at $1.5B VWAP (F9).
  • Shares owned after transaction: not specified in the supplied summary of this Form 4.
  • Filing timeliness: Form filed 2026-05-11 for transactions dated 2026-05-07 and 2026-05-11 — appears timely (filed within the SEC’s 2-business-day window).

Context These filings primarily report derivative awards and the conversion/exercise of previously held derivative securities (including automatic conversions related to preferred stock and warrants around the issuer’s IPO). The small disposition (4 shares) was to cover withholding/exercise obligations (net exercise), not an ordinary open-market sale. The awards are acquisitions (not sales), and no significant cash proceeds to the insider are shown besides the $72 withholding.